Lilly exec says supply, reimbursement are factors for new Mounjaro launches
The top international executive at Eli Lilly on Tuesday said the pharmaceutical company will consider regulatory approvals, reimbursement and sufficient supplies before deciding whether to launch i...
These 2 Top Healthcare Stocks Declared Dividend Raises in 2023
Not only did they hike their payouts, they did so at double-digit percentage rates. Eli Lilly is barging into 2024 with a newly approved medication that's sure to be a hit.
3 Unstoppable Stocks to Buy in 2024
Eli Lilly is growing by leaps and Zepbounds. Novo Nordisk is just getting warmed up after delivering a 53% gain last year.
This pharma stock printed 3 all-time highs in January
Amid a turbulent year for the US pharmaceutical sector, the iShares U.S. Pharmaceuticals ETF (IHE), tracking major domestic pharma companies, has struggled, recording a meager 1% gain in 2023. Howe...
Eli Lilly: The Buzz Is Not Over
Eli Lilly's weight-loss drug Zepbound, with increasing demand and expected insurance coverage, indicates a significant growth opportunity. Continued success in GLP-1 therapies positions LLY as a le...
Why Eli Lilly (LLY) Outpaced the Stock Market Today
Eli Lilly (LLY) closed the most recent trading day at $630.19, moving +0.75% from the previous trading session.
Wall Street Doesn't Expect Eli Lilly Stock to Move Much Higher in 2024. Here's Why Analysts Could Be Wrong.
There's perhaps a surprising lack of enthusiasm on Wall Street about Lilly's near-term prospects. Lilly could soar more than analysts expect with booming sales of Zepbound and a big FDA decision on...
Eli Lilly and Company (LLY) JPMorgan 42nd Annual Healthcare Conference
Eli Lilly and Company (LLY) JPMorgan 42nd Annual Healthcare Conference
Eli Lilly's obesity drug will be a tailwind for the stock, says BMO's Evan Seigerman
Evan Seigerman, BMO biotech analyst, joins 'Power Lunch' to discuss the rise of pharmaceutical M&A and more.
Eli Lilly CEO David Ricks on GLP-1 and obesity drugs
David Ricks, Eli Lilly CEO, joins 'Squawk on the Street' to discuss how big the weight loss and obesity drugs will be for the company, the insurance question around their drugs, and more.
Eli Lilly CEO talks expanding innovation past obesity drugs
Weight-loss drugs became one of the biggest stories in 2023, with Eli Lilly's (LLY) Mounjaro and Zepbound among the pack leaders for GLP-1 pharmaceuticals. Eli Lilly CEO Dave Ricks joins Yahoo Fina...
Lilly CEO says weight-loss drug Zepbound weekly prescriptions hit 25,000 in December
Eli Lilly CEO David Ricks on Monday said the company's powerful weight-loss drug Zepbound hit 25,000 new prescriptions per week at the end of December, and that its 2024 supply may not be enough to...
Isomorphic inks deals with Eli Lilly and Novartis for drug discovery
Isomorphic Labs, the London-based, drug discovery-focused spin-out of Google AI R&D division DeepMind, today announced that it's entered into strategic partnerships with two pharmaceutical giants, ...
3 Stocks to Make You the Millionaire Next Door: 2024 Edition
Some growth stocks keep powering ahead. While not immune to market downturns, certain stocks seem to decline less and recover faster than other securities.
Eli Lilly's direct drug sales may not upend the industry alone – but others could follow suit
LillyDirect is the latest attempt to simplify what critics call a complex system for distributing, pricing and prescribing prescription drugs.
Related Companies